PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2019.34.2.2032019342203Expression of NF2 Modulates the Progression of BRAF V600E Mutated Thyroid Cancer CellsMi-Hyeon You, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kimhttps://synapse.koreamed.org/pdf/10.3803/EnM.2019.34.2.203, https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2019.34.2.203, https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2019.34.2.203
Cancer Cytopathology10.1002/cncy.21475201412212883-891Morphological parameters able to predictBRAFV600E-mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experienceEsther Diana Rossi, Tommaso Bizzarro, Maurizio Martini, Sara Capodimonti, Guido Fadda, Luigi Maria Larocca, Fernando Schmitthttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncy.21475, https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.21475
Thyroid10.1089/thy.2017.010620172791201-1205Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case ReportsPaul S. White, Anita Pudusseri, Stephanie L. Lee, Omar Etonhttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2017.0106, https://www.liebertpub.com/doi/pdf/10.1089/thy.2017.0106
Thyroid Research10.1186/s13044-018-0057-62018111Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cellsHonglai Zhang, Dong Chenhttp://link.springer.com/content/pdf/10.1186/s13044-018-0057-6.pdf, http://link.springer.com/article/10.1186/s13044-018-0057-6/fulltext.html, http://link.springer.com/content/pdf/10.1186/s13044-018-0057-6.pdf
Thyroid10.1089/thy.2019.051420203091288-1296Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF InhibitorsMaria E. Cabanillas, Ramona Dadu, Pryianka Iyer, Kacey B. Wanland, Naifa L. Busaidy, Anita Ying, Maria Gule-Monroe, Jennifer R. Wang, Mark Zafereo, Marie-Claude Hofmannhttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2019.0514, https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0514
Cancer Cytopathology10.1002/cncy.213522013122148-58Value of immunohistochemistry in the detection ofBRAFV600Emutations in fine-needle aspiration biopsies of papillary thyroid carcinomaAnne-Katrin Zimmermann, Ulrike Camenisch, Markus P. Rechsteiner, Beata Bode-Lesniewska, Matthias Rösslehttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncy.21352, https://onlinelibrary.wiley.com/doi/full/10.1002/cncy.21352
Thyroid10.1089/thy.2009.04152010206615-622Sulindac Reverses Aberrant Expression and Localization of β-Catenin in Papillary Thyroid Cancer Cells with the BRAFV600E MutationNancy L. Cho, Chi-Iou Lin, Edward E. Whang, Adelaide M. Carothers, Francis D. Moore, Daniel T. Ruanhttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2009.0415, https://www.liebertpub.com/doi/pdf/10.1089/thy.2009.0415
Thyroid10.1089/thy.2019.0654202030101518-1527Obesity Is Associated with BRAFV600E-Mutated Thyroid CancerSabbir T. Rahman, Nirmala Pandeya, Rachel E. Neale, Donald S.A. McLeod, Chris J. Bain, Peter D. Baade, Philippa H. Youl, Roger Allison, Susan Leonard, Susan J. Jordanhttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2019.0654, https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0654
Thyroid10.1089/thy.2019.05952021315787-799BRAFV600E Overrides NOTCH Signaling in Thyroid CancerFlorian Traversi, Amandine Stooss, Matthias S. Dettmer, Roch-Philippe Charleshttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2019.0595, https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0595
Thyroid10.1089/thy.2012.06142013234517-519IntratumorBRAFV600EHeterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for ParticipationMario Vitalehttps://www.liebertpub.com/doi/full-xml/10.1089/thy.2012.0614, https://www.liebertpub.com/doi/pdf/10.1089/thy.2012.0614